Adagene Inc.

NASDAQ:ADAG

Biotechnology

Healthcare
$1.82 +3.68%

+$0.13 today

Market cap
$68.52M
Beta
0.59
P/E (TTM)
-7.9
EPS (TTM)
-$0.47
52W Low $1.30High $4.75

Volume 1.30M

Average 0.21M

ADAG Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Adagene Inc.NASDAQ: ADAG

Cash & Equivalents · Q4 FY2025 · quarter ended Dec 2025

Cash & equivalents falls 12.5% from a year ago

Cash & equivalents stood at $74.52M at the end of Q4 FY2025, down 12.5% from a year earlier. Over 3 fiscal years it compounded at -19.7% a year.

Context

  • Cash & equivalents amounted to 95.2% of total assets at the end of Q4 FY2025, down 0.2 pp from a year earlier.
  • Cash & equivalents increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -12.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
$74.52M— QoQ
Last fiscal yearDec 2025
$74.52M-12.5% YoY
Year agoDec 2024
$85.19M-12.5% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.5%——
1 year-12.5%——
3-year CAGR-19.7%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
74.52M USD
Year-over-year change
-12.5%
4-year CAGR
-19.1%

Cash & Equivalents vs competitors

How ADAG compares with its peers on the latest reported figures

  • ADAG's Dec 2025 cash & equivalents of $74.52M is the 5th highest of the 9 companies compared; the peer median is $75.85M.
  • Its year-over-year change of -12.5% is the 7th highest of 9, against a peer median of +32.0%.
  • Cash & equivalents amounts to 95.2% of total assets for ADAG, versus a peer median of 67.5%.
ADAG Competitors Peer median
Cash & Equivalents for ADAG and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OSTXOS Therapies IncorporatedMar 2026$917.55M +30783.5%+1063.1%12570.5%
FBIOFortress Biotech, Inc.Mar 2026$255.84M +180.1%-23.6%71.7%
TCRXTScan Therapeutics, Inc.Mar 2026$128.06M -16.9%+8.3%63.4%
XBITXBiotech Inc.Mar 2026$115.46M -25.9%-7.2%82.6%
ADAGAdagene Inc.Dec 2025$74.52M -12.5%-19.7%95.2%
ACETAdicet Bio, Inc.Mar 2026$36.25M +28.8%-46.7%21.4%
GANXGain Therapeutics, Inc.Mar 2026$16.54M +82.3%+41.8%88.3%
NRXPNRx Pharmaceuticals, Inc.Mar 2026$6.71M +21.0%-27.0%56.4%
NTRBNutriband Inc.Apr 2026$4.01M +35.2%+32.1%58.1%
Peer median (excluding ADAG) $75.85M+32.0%+0.5%67.5%

Competitors are the stored peer set for ADAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents174.39M143.76M109.93M85.19M74.52M
Short-term Investments00000
Net Receivables7.51M619.43K222.03K8.31K17.35K
Inventory00000
Other Current Assets2.49M3.78M2.7M527.71K1.2M
Total Current Assets185.95M149.32M113.44M87.78M77.38M
Property, Plant & Equipment (Net)3.49M2.97M2.2M1.41M862.91K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets69.28K109.57K84.89K103.5K25.22K
Total Non-current Assets3.56M3.08M2.29M1.51M888.13K
Total Assets189.51M152.4M115.73M89.27M78.26M
Account Payables3.32M3.67M3.09M4.24M2.88M
Short-term Debt4.5M13.62M8.4M17.79M4.98M
Tax Payables1.66M349.04K52.88K485.97K998.51K
Deferred Revenue5.5M15.11M003.46M
Other Current Liabilities11.62M111.92K119.75K56.27K232.24K
Total Current Liabilities29.82M55.08M31.46M38.18M25.17M
Long-term Debt2.99M14.15M13.54M417.34K1.14M
Deferred Tax Liabilities44.16K0000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities94.11K28.72K0016.55M
Total Non-current Liabilities3.13M14.23M13.71M559.64K17.74M
Total Liabilities32.95M69.31M45.17M38.74M42.91M
Common Stock5.63K5.5K5.55K5.89K5.92K
Retained Earnings(178.83M)(258.81M)(277.75M)(311.18M)(328.79M)
Accumulated OCI(93.98K)(849.31K)(1.8M)(526.9K)(1.91M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity156.56M83.09M70.56M50.52M35.35M
Total Debt7.49M27.97M22.31M18.49M6.26M
Net Debt(166.9M)(115.79M)(87.63M)(66.7M)(68.26M)

Adagene Inc.

NASDAQ:ADAG

Intrinsic Alpha fair value

Locked

Current Price

$1.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.